v3.24.2.u1
NET REVENUES FROM COLLABORATIONS - Additional Information (Detail)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 137 Months Ended
Jun. 05, 2024
USD ($)
Jul. 21, 2023
USD ($)
performance_obligation
Jun. 30, 2024
USD ($)
performance_obligation
Jun. 30, 2024
USD ($)
performance_obligation
Jun. 30, 2023
USD ($)
Jun. 30, 2024
USD ($)
performance_obligation
Jun. 30, 2023
USD ($)
Dec. 31, 2019
USD ($)
target
Jun. 30, 2024
USD ($)
performance_obligation
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Contract with customer liability revenue recognized       $ 200,000 $ 4,800 $ 228,700 $ 10,300    
Roche Collaboration and License Agreement                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Upfront payment   $ 310,000              
Development costs, percentage responsible   40.00%              
Profit and loss sharing percentage   50.00%              
Number of performance obligations | performance_obligation   3              
Transaction price   $ 857,000              
Additional variable consideration   547,000              
Regeneron Pharmaceuticals                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Upfront payment $ 10,000                
Roche | Roche Collaboration and License Agreement                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Upfront payment   $ 310,000              
Development costs, percentage responsible   60.00%              
Profit and loss sharing percentage   50.00%              
Contingent termination fee   $ 50,000              
Transactional price remaining performance obligation     $ 922,000 922,000   922,000     $ 922,000
Contract with customer, liability     503,100 $ 503,100   503,100     $ 503,100
Roche | Roche Collaboration and License Agreement | Milestone                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Revenue, remaining performance obligation, increase (decrease), amount           $ 65,000      
Regeneron Pharmaceuticals | Global Strategic Collaboration                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Upfront payment     $ 10,000            
Number of performance obligations | performance_obligation     2 2   2     2
Transactional price remaining performance obligation 329,686   $ 169,760 $ 169,760   $ 169,760     $ 169,760
Maximum royalties and commercial milestone payments upon potential product sale     325,000            
Discovery period of programs development               7 years  
Extended additional discovery period of programs development               5 years  
Research term extension fee               $ 300,000  
Maximum additional milestone payments to be receive upon achievement of certain criteria               $ 100,000  
Number of targeted programs | target               6  
Maximum percentage of royalty payments               20.00%  
Upfront fee received 260,300                
Variable Consideration Allocated 59,386                
Fixed Consideration 270,300                
Total transaction price increase (decrease)     31,600 31,600   31,600     31,600
Contract with customer, liability     $ 152,200 $ 152,200   $ 152,200     152,200
Regeneron Pharmaceuticals | Global Strategic Collaboration | Funding At Program Initiation                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Potential proceeds from collaboration arrangement               $ 2,500  
Regeneron Pharmaceuticals | Global Strategic Collaboration | Funding At Lead Candidate Identification                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Potential proceeds from collaboration arrangement               2,500  
Regeneron Pharmaceuticals | Global Strategic Collaboration | Maximum                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Collaborative arrangement milestone payments, per collaboration project               $ 150,000  
Royalty rate               20.00%  
Regeneron Pharmaceuticals | Global Strategic Collaboration | C5 Monotherapy Obligation                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Transactional price remaining performance obligation 191,520                
Variable Consideration Allocated 0                
Fixed Consideration $ 191,520                
2013 The Medicines Company Collaboration | Product Alliances | Novartis AG                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Milestone payment earned                 120,000
Potential future payment for the achievement of specified commercialization milestones                 $ 60,000
2013 The Medicines Company Collaboration | Product Alliances | Maximum | Novartis AG                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Royalty rate     20.00% 20.00%   20.00%     20.00%
2013 The Medicines Company Collaboration | Product Alliances | Minimum | Novartis AG                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Royalty rate     10.00% 10.00%   10.00%     10.00%